Eli Lilly (LLY)

Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Tuesday afternoon. Here’s what to expect.

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results this Tuesday after market hours. Here’s what investors should know.

Animal health company Elanco (NYSE:ELAN) will be reporting earnings this Tuesday before market open. Here’s what you need to know.

Even a great stock has a ceiling.

These two healthcare stocks are likely headed higher from their current prices.

Growth stock ETFs offer a catch-all way to buy the dip in top stocks.

Market gains have left some stocks trading at expensive levels.

But it's good news for Eli Lilly, too.

Pfizer is playing catch-up in the GLP-1 drug space, but the drugmaker has a long history of success.

Wall Street is overly focused on GLP-1 drugs even as this medical device maker continues to thrive.

Eli Lilly (LLY) reports landmark Phase 3 data for Omvoh, showing over 90% of Crohn's disease patients achieved 3-year steroid-free remission.

New products are already generating growth.

Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s ability to support its valuation.

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.

These biotech companies have catalysts ahead.

Eli Lilly is leading the pack in the GLP-1 weight-loss drug market, but this good news won't last forever.

Eli Lilly just delivered explosive growth, and analysts see up to 45% upside, but is this pharma giant still a buy at its current price?

Novo Nordisk looks attractively priced even though 2026 is likely to be a tough year.

Never say never. There's certainly a mathematical path to that level, if the company navigates it correctly.

Any of these three pharmaceutical titans could move the needle in your portfolio.

NEW YORK — Pfizer Inc. (NYSE: PFE) has announced breakthrough results from its Phase 3 BREAKWATER clinical trial, demonstrating that its BRAFTOVI (encorafenib) regimen significantly improves both progression-free survival (PFS) and overall survival (OS) in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC). The data, bolstered by a fresh topline report

Ozempic's rival is generating blockbuster revenue and gaining market share.

Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral.

Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.